Other Income & Expense
Net Interest and Investment Income (Loss)
Vertex Pharmaceuticals Net Interest and Investment Income (Loss) decreased by 2.6% to $114.80M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalHigher is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ1 2026May 5, 2026
How to read this metric
Positive values contribute to overall net income, while negative values indicate investment losses or high financing costs.
Detailed definition
The net result of interest income earned on cash balances and gains or losses from investment portfolios. This metric ca...
Peer comparison
Varies significantly based on the size of a company's treasury and investment holdings.
Metric ID:
gev_net_interest_and_investment_incomeHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $117.90M | $114.80M |
| QoQ Change | — | -2.6% |
| YoY Change | — | -2.6% |
Range$114.80M – $117.90M
Avg YoY Growth-2.6%
Median YoY Growth-2.6%
Business Segments
| Segment | Q1 '26 |
|---|---|
| Pharmaceuticals | $114.80M |
| Total | $114.80M |
Net Interest and Investment Income (Loss) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's net interest and investment income (loss)?
- Vertex Pharmaceuticals (VRTX) reported net interest and investment income (loss) of $114.80M in Q1 2026.
- What does net interest and investment income (loss) mean?
- Net income generated from interest and investment activities.